The 3^rd European CAR T-cell Meeting, organized by the European Society for Blood and Marrow Transplantation (EBMT), and the European Haematology Association (EHA), and shed light on the current and future indications of CAR T-cell therapies in hematological oncology. The nursing program highlighted key questions in the management of patients treated with cellular therapies including communication within multidisciplinary teams, the use of immune effector cells in solid tumors, the importance of treatment settings as well as survivorship considerations following CAR T-cell therapy.

In this roundtable discussion, Erik Aerts of the Hematology Nurses and Healthcare Professionals Group, Winterthur, Switzerland, leads an exciting discussion on key learnings and takeaways from the 3^rd European CAR T-cell Meeting and is joined by John Murray, of the Christie Hospital NHS Foundation Trust, Manchester, UK, Michelle Kenyon, of King’s College Hospital NHS Foundation Trust, London, UK, and Rose Ellard, of the Royal Marsden NHS Foundation Trust, London, UK.